

# **L** Core Project R03OD032624

#### O Details

| Projects        | Name   | Award        | Publications    | Repositories   | Analytics    |
|-----------------|--|--------------|-----------------|----------------|--------------|
| 1R03OD032624-01 | Using Common Fund datasets for xenobiotic localization | \$304,000.00 | 12 publications | 0 repositories | 0 properties |

## Publications

Published works associated with this project.

| ID                  | Title   | Authors              | RC<br>R        | SJ<br>R | Cita<br>tion<br>s | Cit./<br>yea<br>r | Journal              | Publ<br>ishe<br>d | Upda<br>ted        |
|---------------------|---|----------------------|----------------|---------|-------------------|-------------------|----------------------|-------------------|--------------------|
| 36116580 🗹<br>DOI 🗹 | Mucoadhesive carriers for oral drug delivery. | Kumar, Raj<br>1 more | 10.<br>08<br>9 | 0       | 80                | 26.6<br>67        | J Control<br>Release | 202<br>2          | Sep<br>24,<br>2025 |

|                                   |  | Nurunnabi,<br>Md   |           |               |    |      |                             |          | (just<br>now)                       |
|-----------------------------------|--|--|-----------|---------------|----|------|-----------------------------|----------|-------------------------------------|
| 38065244 🖸                        | Emerging delivery approaches for targeted pulmonary fibrosis treatment.                                    | Diwan,<br>Rimpy<br>2 more<br>Nurunnabi,<br>Md                  | 8.0<br>94 | 0             | 27 | 27   | Adv Drug<br>Deliv Rev       | 202<br>4 | Sep<br>24,<br>2025<br>(just<br>now) |
| 38104896 🖸                        | Potentials of ionic liquids to overcome physical and biological barriers.                                  | Beaven,<br>Elfa<br>7 more<br>Nurunnabi,<br>Md                  | 4.5<br>86 | 0             | 13 | 13   | Adv Drug<br>Deliv Rev       | 202<br>4 | Sep<br>24,<br>2025<br>(just<br>now) |
| 36971908 🗗                        | Oral delivery of RNAi for cancer therapy.  | Afrin,<br>Humayra<br>4 more<br>Nurunnabi,<br>Md                | 3.3<br>38 | 0             | 21 | 10.5 | Cancer<br>Metastasis<br>Rev | 202<br>3 | Sep<br>24,<br>2025<br>(just<br>now) |
| 37238639 <b>♂</b><br>DOI <b>♂</b> | β-Glucan and Fatty Acid Based<br>Mucoadhesive Carrier for<br>Gastrointestinal Tract Specific Local and<br> | Esquivel,<br>Stephanie<br>Vargas<br>5 more<br>Nurunnabi,<br>Md | 2.7       | 1.<br>33<br>3 | 10 | 5    | Biomolecul<br>es            | 202<br>3 | Sep<br>24,<br>2025<br>(just<br>now) |
| 36753355 <b>♂</b><br>DOI <b>♂</b> | Potential and Progress of 2D Materials in Photomedicine for Cancer Treatment.                              | Bhatt,<br>Himanshu   | 2.2<br>44 | 0             | 9  | 4.5  | ACS Appl<br>Bio Mater       | 202<br>3 | Sep<br>24,                          |

|                     |  | N<br>5 more<br>Nurunnabi,<br>Md                       |           |   |    |     |                                 |          | 2025<br>(just<br>now)               |
|---------------------|--|---|-----------|---|----|-----|---------------------------------|----------|-------------------------------------|
| 37350332 🗗          | β-Glucan-Mediated Oral Codelivery of<br>5FU and Bcl2 siRNA Attenuates Stomach<br>Cancer. | Afrin,<br>Humayra<br>6 more<br>Nurunnabi,<br>Md       | 2.0<br>34 | 0 | 8  | 4   | ACS Appl<br>Mater<br>Interfaces | 202<br>3 | Sep<br>24,<br>2025<br>(just<br>now) |
| 36445310 🗗          | Myofibroblast specific targeting approaches to improve fibrosis treatment.               | Beaven,<br>Elfa<br>3 more<br>Nurunnabi,<br>Md         | 1.8<br>21 | 0 | 18 | 6   | Chem<br>Commun<br>(Camb)        | 202<br>2 | Sep<br>24,<br>2025<br>(just<br>now) |
| 37562554 🗹<br>DOI 🗹 | A photothermal driven chemotherapy for the treatment of metastatic melanoma.             | Bhatt,<br>Himanshu<br>N<br>6 more<br>Nurunnabi,<br>Md | 0.7<br>42 | 0 | 5  | 2.5 | J Control<br>Release            | 202<br>3 | Sep<br>24,<br>2025<br>(just<br>now) |
| 37554053 🗹<br>DOI 🗹 | Carbon Coated Iron-Cobalt<br>Nanoparticles for Magnetic Particle<br>Imaging.             | Kumar, Raj<br>5 more<br>Nurunnabi,<br>Md              | 0.1<br>91 | 0 | 2  | 1   | ACS Appl<br>Bio Mater           | 202<br>3 | Sep<br>24,<br>2025<br>(just<br>now) |

| 38446352 <b>♂</b><br>DOI <b>♂</b> | Liver fibrosis pathologies and potentials of RNA based therapeutics modalities.                     | Diwan,<br>Rimpy<br>3 more<br>Nurunnabi,<br>Md         | 0 | 0 | 1 | 1 | Drug Deliv<br>Transl Res | 202<br>4 | Sep<br>24,<br>2025<br>(just<br>now) |
|-----------------------------------|---|---|---|---|---|---|--------------------------|----------|-------------------------------------|
| 38648957 <b>♂</b><br>DOI <b>♂</b> | Cadherin-11 targeted cell-specific liposomes enabled skin fibrosis treatment by inducing apoptosis. | Bhatt,<br>Himanshu<br>N<br>6 more<br>Nurunnabi,<br>Md | 0 | 0 | 1 | 1 | J Control<br>Release     | 202<br>4 | Sep<br>24,<br>2025<br>(just<br>now) |

## Notes

RCR Relative Citation Ratio

SJR Scimago Journal Rank

#### Publications (cumulative)







| Name | Tags | Last Commit | Avg Issue | Avg PR | Languages | License | Readme | Contributing | Dependencies |
|------|------|-------------|-----------|--------|-----------|---------|--------|--------------|--------------|
|      |      |             |           |        | No data   |         |        |              |              |

#### Notes

Repository For storing, tracking changes to, and collaborating on a piece of software.

PR "Pull request", a draft change (new feature, bug fix, etc.) to a repo.

Closed/Open Resolved/unresolved.

Avg Issue/PR Average time issues/pull requests stay open for before being closed.

Only the main /default branch is considered for metrics like # of commits.

# of dependencies is totaled from all manifests in repo, direct and transitive, e.g. package.json + package-lock.json.

#### Analytics

Traffic metrics of websites associated with this project.

#### Notes

Active Users <u>Distinct users who visited the website</u> 2.

New Users <u>Users who visited the website for the first time</u> **.** 

Engaged Sessions <u>Visits that had significant interaction</u> **?**.

"Top" metrics are measured by number of engaged sessions.

Built on Sep 24, 2025

Developed with support from NIH Award U54 OD036472